Hydrocodone-Acetaminophen Label Puts Overdose and Interaction Risks at the Center

The updated DailyMed label for hydrocodone bitartrate and acetaminophen places the drug’s major hazards in plain view: addiction, abuse, misuse, life-threatening respiratory depression, accidental ingestion, neonatal opioid withdrawal syndrome, CYP3A4 interactions, hepatotoxicity, and the danger of combining opioids with benzodiazepines or other central nervous system depressants. This is not a routine safety footnote. It is the defining framework for how the tablet must be prescribed, stored, counseled, and monitored.

Hydrocodone remains a full mu-opioid agonist, and the label is explicit about the consequence of that pharmacology. Analgesia comes with no ceiling effect, but respiratory suppression does. As dose rises, so does the risk of sedation, slowed breathing, coma, and death, especially during treatment initiation and after dose increases. The combination with acetaminophen adds a second layer of danger: the opioid can depress respiration, while the non-opioid component can injure the liver when total acetaminophen exposure climbs too high.

Opioid Analgesia Carries a Narrow Safety Margin

The label’s pharmacology section gives the bedside reason for the boxed warning. Hydrocodone acts on CNS opioid receptors distributed throughout the brain and spinal cord, producing analgesia but also depressing the brain stem respiratory centers. That depression reduces responsiveness to carbon dioxide and electrical stimulation, which explains why patients can become progressively hypoventilated with relatively small increments in exposure.

One sentence captures the clinical reality: respiratory depression is the toxicity that can end treatment abruptly.

The label also details the gastrointestinal and cardiovascular effects that often precede a more serious event. Hydrocodone slows gastrointestinal motility, increases smooth muscle tone, and contributes to constipation. It can produce peripheral vasodilation, orthostatic hypotension, and syncope. Miosis is expected, though the label cautions that pinpoint pupils are not diagnostic by themselves. In overdose, hypoxia can even reverse the classic pattern and produce mydriasis instead.

Acetaminophen Adds a Second Route to Serious Harm

Acetaminophen is described as a non-opiate, non-salicylate analgesic and antipyretic with a mechanism that remains incompletely defined, though central actions are thought to be involved. Its toxicity profile is much clearer. The label warns that acute liver failure has occurred, at times requiring liver transplant or ending in death. Most reported liver injury has involved doses exceeding 4,000 mg per day, often because more than one acetaminophen-containing product was taken at the same time.

That warning has immediate implications for everyday prescribing. Patients often recognize opioid risk more readily than acetaminophen risk, yet the liver toxicity threshold can be crossed silently when combination products are layered with over-the-counter cold, flu, or pain medications. Because the tablet contains 325 mg of acetaminophen across the listed strengths of 5 mg, 7.5 mg, and 10 mg hydrocodone, the total daily tablet count matters as much as the opioid dose.

CYP3A4 and CYP2D6 Pathways Shape Exposure

Hydrocodone metabolism is not pharmacologically static. The label identifies CYP3A4-mediated N-demethylation to norhydrocodone as the primary pathway, with a smaller contribution from CYP2D6-mediated O-demethylation to hydromorphone. Those pathways create a predictable hazard when interacting drugs enter the picture. CYP3A4 inhibitors can raise hydrocodone plasma concentrations, prolong adverse reactions, and increase the likelihood of potentially fatal respiratory depression. Stopping a CYP3A4 inducer can have a similar effect by allowing hydrocodone levels to rise after induction disappears.

In practice, the interaction warning is not theoretical metabolism trivia. It changes what happens at the bedside when a patient starts or stops common medications that alter hepatic enzyme activity. Sedation, hypoventilation, and confusion can emerge after a regimen that once seemed stable. The label directs monitoring for respiratory depression or sedation whenever CYP3A4 inhibitors or inducers are used alongside hydrocodone.

Benzodiazepines, Alcohol, and Other CNS Depressants Raise the Stakes

The combination of opioids with benzodiazepines or other CNS depressants remains one of the clearest safety hazards in outpatient medicine. The label warns that the result may be profound sedation, respiratory depression, coma, and death. Alcohol is included in that warning, which broadens the risk beyond prescription co-therapy and into ordinary daily exposure.

Prescribing should be reserved for patients in whom alternative treatment options are inadequate. The wording is deliberate. It reflects a narrow tolerance for dual-depressant exposure because the pharmacology is additive rather than compensatory. A patient who appears only mildly sedated can still be sliding toward ventilatory failure.

Pregnancy, Newborns, and the Risk of Withdrawal

Extended opioid use during pregnancy can lead to neonatal opioid withdrawal syndrome, which the label describes as potentially life-threatening if it is not recognized and treated. Planning for delivery matters because management by neonatology experts should be available when ongoing maternal opioid exposure has occurred. The warning shifts the focus from maternal comfort alone to fetal and neonatal preparedness.

This is one of the clearest bedside consequences in the label. Opioid exposure does not stop at the placenta, and the newborn may enter the world already dependent on the drug. What looks like routine maternal analgesic therapy can therefore become a neonatal management issue before delivery has even occurred.

Accidental Ingestion and Storage Are Part of the Prescribing Decision

Even one dose can be fatal if a child accidentally ingests the tablet. The label treats that possibility as a central safety concern, not an edge case. Because hydrocodone is a potent opioid, accidental exposure in a pediatric household is not a minor mishap; it is a potential overdose emergency.

The REMS language reinforces that prescribers are expected to counsel patients and caregivers on safe use and to ensure they read the Medication Guide with each prescription. For a Schedule II opioid combination, education is not ceremonial. It is part of the risk-control strategy.

The Label’s Dosing and Formulation Details Signal Controlled Use

The product is supplied as an oral tablet and listed as a DEA Schedule CII human prescription drug under an abbreviated new drug application. The strengths described are 5 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg. The label also notes that the tablets meet USP Dissolution Test 1 and lists inactive ingredients including colloidal silicon dioxide, croscarmellose sodium, crospovidone, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, and stearic acid.

Pharmacokinetic data in healthy adult males show that hydrocodone reaches peak serum concentration at about 1.3 hours after a 10 mg oral dose, with a mean half-life of 3.8 hours. Acetaminophen is rapidly absorbed, has a plasma half-life of 1.25 to 3 hours, and is eliminated mainly through hepatic metabolism with renal excretion of metabolites. Those kinetics help explain why repeated dosing can accumulate risk over a short interval if the schedule is not carefully managed.

The label leaves little ambiguity: the therapeutic goal is pain relief, but the cost of misjudged dosing, interacting drugs, or overlapping acetaminophen products can be severe. For clinicians, the central task is not simply choosing an analgesic. It is controlling a drug combination whose benefits and harms are separated by a narrow and highly monitored margin.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by DailyMed Drug Label Updates.